Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-11-06

FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for the amlodipine/atorvastatin combination by Mylan Pharmaceuticals, resulting in labeling changes to reflect the appro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine and Atorvastatin (amlodipine besylate and atorvastatin calcium)

Snippet

SUPPL AP for AMLODIPINE AND ATORVASTATIN (AMLODIPINE AND ATORVASTATIN)